Month: August 2020

Worldwide Ocaliva net sales of $77.2 million in the second quarter 2020, representing 17% growth over the prior year quarter Intercept issues 2020 Ocaliva Net Sales Guidance of $300 to $320 millionIntercept lowers 2020 non-GAAP Adjusted Operating Expense Guidance by $100 million to $460 million to $500 millionPreparations Underway for Type A Meeting with FDA on NASH Fibrosis ProgramConference call scheduled for 8:30 a.m. ET todayNEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter ended June 30, 2020.“Our PBC business achieved its highest quarterly net sales to date in the second quarter,” said...

Completed Enrollment of Randomized, Blinded, Placebo-controlled Trial of GC4419 in Combination with Radiotherapy in Locally Advanced Pancreatic Cancer; Topline Data Readout Expected in 2H20Phase 3 ROMAN Trial Remains on Track for Completion of Enrollment in 1H21MALVERN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the second quarter ended June 30, 2020, and provided business updates.“During the second quarter, we continued to advance the development of our small molecule superoxide dismutase mimetics in clinical trials evaluating their ability to address radiation toxicities...

VANCOUVER, British Columbia, Aug. 10, 2020 (GLOBE NEWSWIRE) — Corvus Gold Inc. (“Corvus” or the “Company”) – (TSX: KOR, OTCQX: CORVF) announces that it has received approval to up-list to the Nasdaq Capital Markets and will begin trading under the symbol “KOR” on Wednesday, August 12, 2020.  The Company’s common shares will continue to be traded on the OTCQX until the market close on August 11, 2020 after which these shares will begin trading under the symbol “KOR” on the Nasdaq Capital Markets.  Corvus’ common shares will continue to trade on the TSX under the same symbol “KOR”.Jeffrey Pontius, President and CEO of Corvus, said, “I am proud to announce that Corvus is now the 6th gold equity on the Nasdaq.  This rare feat of up-listing to a major, well recognized exchange gives the Company increased access to the largest pool...

Suominen Corporation’s press release on August 10, 2020 at 2:00 p.m. (EEST) Suominen invites analysts and investors to participate in its virtual Capital Markets Day on Wednesday, September 2, 2020 from 1:00 p.m. till 4:00 p.m. At the event, Suominen’s management will provide an update on the company’s strategy, business and financials. The language of the event is English.Suominen CorporationCorporate CommunicationsEmilia Peltola, VP, Communications, IR and Sustainability, tel. +358 (0)10 214 3082

Suominen Oyj:n lehdistötiedote 10.8.2020 klo 14.00 Suominen kutsuu analyytikot ja sijoittajat virtuaaliseen pääomamarkkinapäivään keskiviikkona 2. syyskuuta 2020 klo 13–16. Suomisen johto tarjoaa tilaisuudessa katsauksen yhtiön strategiaan, liiketoimintaan ja talouteen. Tapahtuman kieli on englanti.Suominen OyjViestintäEmilia Peltola, viestintä- ja sijoittajasuhdejohtaja, puh. 010 214 3082

Philadelphia, PA, Aug. 10, 2020 (GLOBE NEWSWIRE) — VSBLTY Groupe Technologies Corp. (CSE: VSBY) (Frankfurt: 5VS) (OTC: VSBGF) (“VSBLTY”), a leading provider of security and retail marketing technology, and its South African partner Onyx-Cognivas have reached agreement to deploy multiple digital media solutions in a chain of fuel/convenience stores operating in South Africa, it was announced jointly today by VSBLTY Co-founder & CEO Jay Hutton and Onyx-Cognivas Pty. Co-founder Andrew Coudounaris.Amplifying the announcement, Coudounaris said, “This marks an important milestone in how the retailer of the future is adopting, not only digital activation for enhanced customer engagement, but also the utilization of computer vision to provide validation and verification for media partners.”Hutton added, “This agreement spans five years...

PETAH TIKVA, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announces the award of over $10 Million for a five-year service project for 4G backhaul services in Latin America. The contract calls for providing coverage to half a million people in hundreds of sites in rural areas, with significant expansion potential valued at additional tens of millions of dollars over time.Gilat is working closely with the government and the private sector to provide connectivity this year to hundreds of villages via the 4G network. Gilat is heavily engaged in supplying the population with broadband connectivity and access to applications such as e-health and e-education. Furthermore, four hundred additional villages are expected...

SALT LAKE CITY, Aug. 10, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today a new study published in the peer-reviewed journal Genetics in Medicine demonstrates the limitations of ethnicity-based medical guidelines in identifying couples at risk for a pregnancy affected by serious genetic conditions. The analysis of 93,419 individuals found substantial discordance between self-reported ethnicity and actual genetic ancestry.In the new study, researchers at Myriad assessed the ability of a 96-disease screen to identify carriers in an ethnically diverse population, comparing the results to those obtainable via ethnicity-based screening. They also compared the genetic ancestry of the population to self-reported ethnicity. Results showed that only 23...

NEWTOWN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that second quarter of fiscal year 2020 financial results will be released after the market closes on Wednesday, August 12th.Management will host a conference call at 5:00 p.m. Eastern Time on August 12th to discuss the results of the quarter. Those who would like to participate may dial 877-407-2988 (201-389-0923 for international callers) and provide access code 13705949. A live webcast of the call will also be provided on the Events section of the Company’s investor relations website and can be accessed directly via the following link: https://78449.themediaframe.com/dataconf/productusers/hls/mediaframe/39028/indexl.html.For...

Two NDA submissions, for AXS-05 in MDD and for AXS-07 in migraine, on track for 4Q 2020  Enrollment completed for both the AXS-05 Phase 3 long-term safety trial in MDD, and for the AXS-07 Phase 3 long-term safety trial in migraineResults from three Phase 2 open-label efficacy trials of AXS-05 in TRD, antidepressant unresponsive MDD, and suicidal ideation, expected in 4Q 2020Phase 3 trials for AXS-05 in Alzheimer’s disease agitation and for AXS-12 in narcolepsy on track for 4Q 2020Three FDA Breakthrough Therapy designations, in MDD, Alzheimer’s disease agitation, and narcolepsy, highlight Axsome’s broad, differentiated, late-stage CNS pipeline                                         Company to host conference call today at 8:00 AM Eastern                        NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc....